cytarabine has been researched along with genistein in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Honma, Y; Hozumi, M; Kasukabe, T; Okabe-Kado, J; Onozuka, Y | 1 |
| Chorváth, B; Duraj, J; Hunáková, L; Sedlák, J; Suliková, M | 1 |
| Roig, J; Traugh, JA | 1 |
| Anagnostopoulos, N; Androutsos, G; Galanopoulos, A; Kalmantis, T; Meletis, J; Paterakis, G; Rombos, Y; Sagriotis, A; Symeonidis, A; Tiniakou, M; Tsimberidou, AM; Yataganas, X; Zoumbos, N | 1 |
| Bagrintseva, K; Eichenlaub, S; Ellwart, JW; Hiddemann, W; Kohl, TM; Schnittger, S; Schwab, R; Spiekermann, K | 1 |
| Cheang, PT; Chen, CS; Fred Wong, WS; Han, JH; Khan, M; Shen, J; Stephen Wong, CH; Tai, YC; Xie, Z; Zhou, J | 1 |
6 other study(ies) available for cytarabine and genistein
| Article | Year |
|---|---|
Hemin enhances the sensitivity of erythroleukemia cells to 1-beta-D-arabinofuranosylcytosine by both activation of deoxycytidine kinase and reduction of cytidine deaminase activity.
Topics: Cell Differentiation; Cytarabine; Cytidine Deaminase; Deoxycytidine Kinase; Drug Tolerance; Enzyme Activation; Erythrocytes; Genistein; Hemin; Humans; Isoflavones; Leukemia, Erythroblastic, Acute; Protein-Tyrosine Kinases; Tumor Cells, Cultured | 1991 |
Stimulation of 1-(beta-D-arabinofuranosyl)cytosine (AraC)-induced apoptosis in the multidrug resistant human promyelocytic leukemia cell lines with protein kinase inhibitors.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; DNA, Neoplasm; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Genistein; HL-60 Cells; Humans; Isoflavones; Protein Kinase C; Staurosporine | 1996 |
p21-activated protein kinase gamma-PAK is activated by ionizing radiation and other DNA-damaging agents. Similarities and differences to alpha-PAK.
Topics: 3T3 Cells; Androstadienes; Animals; Cisplatin; Cytarabine; DNA Damage; Dose-Response Relationship, Radiation; Enzyme Activation; Gamma Rays; Genistein; Humans; Mice; Mutagens; p21-Activated Kinases; Protein Serine-Threonine Kinases; Radiation, Ionizing; U937 Cells; Ultraviolet Rays; Wortmannin | 1999 |
Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Transplantation; Calcium Channel Blockers; Carbocyanines; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fluoresceins; Fluorescent Dyes; Genistein; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Probenecid; Prognosis; Prospective Studies; Rhodamine 123; Survival Analysis; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles; Verapamil | 2002 |
Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Transformed; Cytarabine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Genistein; Humans; Indoles; Leukemia, Myeloid; MAP Kinase Signaling System; Milk Proteins; Mutagenesis; Phenotype; Phosphorylation; Protein Structure, Tertiary; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; STAT5 Transcription Factor; Staurosporine; Trans-Activators; Tyrphostins | 2004 |
Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytarabine; Drug Synergism; Gene Expression Regulation, Neoplastic; Genistein; Humans; Leukemia; MAP Kinase Signaling System; Mice; Mice, SCID; Neoplasms, Experimental; Survival Rate; Transplantation, Heterologous; Tumor Burden | 2007 |